A personalized mRNA vaccine for melanoma cut the risk of death or recurrence by 42% compared with standard treatment in a late-stage trial, Merck and Moderna said Thursday.
Melanoma is the deadliest form of skin cancer. The partners said the vaccine, which is built to match each patient's own tumor, outperformed the existing standard of care, and that they are already engaging with regulatory authorities to seek approval. Moderna CEO Stéphane Bancel said in a statement that the results "mark a defining moment" for the idea of cancer treatments "uniquely matched to each patient's tumor."
That is the companies' own framing, so the number deserves a careful read. The 42% figure combines two outcomes, death and recurrence, and it is a relative reduction. A relative figure says how much the risk fell against standard treatment, not how many patients stayed cancer-free. The summary of the results includes no absolute rates, enrollment numbers, or follow-up length.
Still, the result matters beyond one cancer. Most people know mRNA from COVID shots, which carry the same instructions for everyone. A cancer vaccine like this one is individualized, which makes it a different kind of product to manufacture, test, and approve. A clear win in a late-stage trial gives that approach its strongest evidence so far and, as the announcement put it, bolsters hope that individualized cancer medicines could become a new category of therapy.
The open question is what comes after the trial. Regulators will want the full data, and a treatment tailored to each tumor has to be produced one patient at a time, so scaling it is a separate problem from proving it works.